All coverage
Industry fights over global vaccine patents are just warming up
By Christopher Rowland
Explainer: COVID-19 vaccine patents dominate global trade talks
By Philip Blenkinsop
All you need to know about the battle over COVID jab IP rights
By Virginia Pietromarchi
TRIPS waiver: there's more to the story than vaccine patents
By Siva Thambisetty, Hyo Yoon Kang & Jocelyn Bosse
Waiver of patent rights on Covid-19 vaccines, in near term, may be more symbolic than substantive
By Helen Branswell, Matthew Herper & Damian Garde
Explained: Intellectual property waiver for Covid-19 vaccines
By Prabha Raghavan & Aanchal Magazine
Biden Confronts Coronavirus Vaccine Patents
By Thomas Kaplan, Rebecca Robbins & Sheryl Gay Stolberg
Why the TRIPS Waiver Objections Don't Add Up
By Neal Templin
Covid: The vaccine patent row explained
By Dharshini David
U.S. wants COVID vaccine patent waiver to benefit world, not boost China biotech
By Carl O'Donnell, David Lawder & Andrea Shalal-Esa
Germany rejects U.S. proposal to waive patents on COVID-19 vaccines
By Madeline Chambers, Andreas Rinke & Douglas Busvine
U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents
By Jeff Mason, Andrea Shalal-Esa & David Lawder
U.S. backs waiving patent protections for Covid vaccines, citing global health crisis
By Thomas Franck, Kevin Breuninger & Amanda Macias
Biden administration to waive vaccine patent protection - The Washington Post
By Dan Diamond, Tyler Pager & Jeff Stein